02 August 2018
Visiongain’ has launched a new pharma report Global Anaesthesia Drugs Market 2018-2028: Local Anaesthesia, General Anaesthesia, Inhalation Anaesthesia, Intravenous Anaesthesia, Topical Anaesthesia
This anaesthesia drugs market can be broadly segmented into type and routes of administration. The market is segregated further by type as local anaesthesia and general anaesthesia. Inhalation intravenous and topical are the main forms of routes of administration. The market has also been geographically segmented into North America (US, Canada), Europe (Germany, France, UK, Italy, Spain, Rest of Europe), Asia-Pacific (India, China, Japan, Rest of Asia-Pacific), Rest of World (Brazil, Mexico, Russia, South Africa).
The lead analyst of the report commented “The global anaesthesia drugs market is projected to grow at lucrative rate during the forecast period owing to a rising number of surgical procedures globally, developing healthcare infrastructure in emerging economies, and growing number of geriatric population. The escalating prevalence of cancer, stroke, arthritis, and neurological diseases leads to a rising number of surgical procedures. In addition, rising number of road accidents and trauma cases will further drive the growth of the market.”
Leading companies featured in the report include Baxter International, Inc., AbbVie, PAION AG, Pfizer, Hameln Pharmaceuticals, AstraZeneca, Fresenius Kabi, Maruishi Pharmaceuticals, Pacira Pharmaceuticals, Inc
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Visiongain believes the market will see more traditional pharma companies beginning to embrace the generic business in order to take advantage of higher growth rates in this area.
14 June 2019
The market players are increasingly focusing on precision therapies where drug and precision tests are developed simultaneously.
06 June 2019
Market penetration and adoption of new technologies entering the market for antifungal drugs will be crucial for market growth.
04 June 2019
here is a growing demand for ophthalmic equipment such as vision care products and ophthalmology surgical devices, mainly due to the increasing incidence of myopia across the world.